#1
#1 out of 1
health18h ago
Dexcom RCT suggests CGM benefits for broad diabetes population
- Dexcom presented 26‑week data showing a 0.9 percentage point HbA1c reduction in non‑insulin type 2 diabetes using CGM versus self‑monitoring.
- Dexcom reports CGM users spent five additional hours daily in the target glucose range (70–180 mg/dL).
- Dexcom plans to add nutrition coaching to the Stelo over‑the‑counter CGM app after acquiring Nutrisense.
- Dexcom’s trial data comes as the company seeks Medicare coverage decisions for non‑insulin users.
- Apple announced perimenopause risk indicators and new child safety features at its WWDC keynote.
Vote 0